UY36228A - Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen - Google Patents

Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen

Info

Publication number
UY36228A
UY36228A UY0001036228A UY36228A UY36228A UY 36228 A UY36228 A UY 36228A UY 0001036228 A UY0001036228 A UY 0001036228A UY 36228 A UY36228 A UY 36228A UY 36228 A UY36228 A UY 36228A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
sintasa
heteroarilo
cyp11b2
aldosterone
Prior art date
Application number
UY0001036228A
Other languages
English (en)
Inventor
Cogan Derek
Mckibben Bryan
Burke Jennifer
Cerny Matthew
Fader Lee
Frederick Kosea
Lord John
Surprenant Simon
Yu Maolin
Zhang Yunlong
Daniel Richard Marshall
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY36228A publication Critical patent/UY36228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a los compuestos de la Fórmula I:y a las sales de estos aceptables desde el punto de vista farmacéutico, en donde Cy,R1 y R2 son como se definen en la presente. La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos, a métodos para usar estos compuestos en el tratamiento de varias enfermedades y trastornos, a procesos para preparar estos compuestos y a intermediarios útiles en estos procesos.
UY0001036228A 2014-07-24 2015-07-24 Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen UY36228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028556P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
UY36228A true UY36228A (es) 2016-01-29

Family

ID=53761616

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036228A UY36228A (es) 2014-07-24 2015-07-24 Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen

Country Status (34)

Country Link
US (1) US9334285B2 (es)
EP (1) EP3172212B1 (es)
JP (1) JP6250862B2 (es)
KR (1) KR102378648B1 (es)
CN (1) CN106488921B (es)
AP (1) AP2016009616A0 (es)
AR (1) AR101290A1 (es)
AU (1) AU2015292632B2 (es)
BR (1) BR112017000584B1 (es)
CA (1) CA2956118C (es)
CL (1) CL2017000040A1 (es)
CO (1) CO2017000443A2 (es)
CY (1) CY1121063T1 (es)
DK (1) DK3172212T3 (es)
EA (1) EA031105B1 (es)
ES (1) ES2684050T3 (es)
HR (1) HRP20181441T1 (es)
HU (1) HUE039981T2 (es)
IL (1) IL249665B (es)
LT (1) LT3172212T (es)
MX (1) MX368093B (es)
MY (1) MY191352A (es)
NZ (1) NZ727188A (es)
PE (1) PE20170294A1 (es)
PH (1) PH12017500089A1 (es)
PL (1) PL3172212T3 (es)
PT (1) PT3172212T (es)
RS (1) RS57570B1 (es)
SG (1) SG11201700595RA (es)
SI (1) SI3172212T1 (es)
TW (1) TWI600658B (es)
UA (1) UA118801C2 (es)
UY (1) UY36228A (es)
WO (1) WO2016014736A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3207039B1 (en) * 2014-10-15 2019-03-06 Boehringer Ingelheim International GmbH Aldosterone synthase inhibitors
JP6707084B2 (ja) * 2014-12-02 2020-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
JP6914974B2 (ja) 2016-06-28 2021-08-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
US8153674B2 (en) * 2006-03-29 2012-04-10 Novartis Ag Organic compounds
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones

Also Published As

Publication number Publication date
EP3172212B1 (en) 2018-06-13
AU2015292632B2 (en) 2019-11-21
TW201619165A (zh) 2016-06-01
HRP20181441T1 (hr) 2018-11-02
UA118801C2 (uk) 2019-03-11
AP2016009616A0 (en) 2016-12-31
CO2017000443A2 (es) 2017-04-10
US9334285B2 (en) 2016-05-10
KR20170032459A (ko) 2017-03-22
LT3172212T (lt) 2018-08-27
CA2956118C (en) 2022-11-15
JP6250862B2 (ja) 2017-12-20
PL3172212T3 (pl) 2018-11-30
MX368093B (es) 2019-09-19
PT3172212T (pt) 2018-10-08
BR112017000584B1 (pt) 2022-07-26
EP3172212A1 (en) 2017-05-31
IL249665A0 (en) 2017-02-28
KR102378648B1 (ko) 2022-03-28
AU2015292632A1 (en) 2016-12-22
EA031105B1 (ru) 2018-11-30
MY191352A (en) 2022-06-18
BR112017000584A2 (pt) 2017-11-07
NZ727188A (en) 2020-01-31
PE20170294A1 (es) 2017-04-12
HUE039981T2 (hu) 2019-02-28
PH12017500089B1 (en) 2017-05-22
AR101290A1 (es) 2016-12-07
ES2684050T3 (es) 2018-10-01
JP2017521466A (ja) 2017-08-03
SI3172212T1 (sl) 2018-10-30
WO2016014736A1 (en) 2016-01-28
CA2956118A1 (en) 2016-01-28
EA201790253A1 (ru) 2017-07-31
CY1121063T1 (el) 2019-12-11
IL249665B (en) 2019-08-29
CN106488921A (zh) 2017-03-08
TWI600658B (zh) 2017-10-01
DK3172212T3 (en) 2018-08-27
SG11201700595RA (en) 2017-02-27
US20160024105A1 (en) 2016-01-28
CL2017000040A1 (es) 2017-07-07
RS57570B1 (sr) 2018-10-31
MX2017000929A (es) 2017-05-04
PH12017500089A1 (en) 2017-05-22
CN106488921B (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
UY36226A (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112017006305A2 (pt) compostos heteroarila como inibidores de btk e usos dos mesmos
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
UY34917A (es) Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
UY36228A (es) Derivados de heteroarilo como inhibidores de aldosterona sintasa (cyp11b2) y composiciones farmacéuticas que los contienen
CL2015000019A1 (es) Composicion farmaceutica que comprende rifaximina cristalina, polimorfa o amorfa, como un hidrato o solvato y/o en una mezcla de la misma y uno o mas aminoacidos; procedimiento de preparacion de la composicion; cristales de rifaximina; su procedimiento de preparacion.
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
DOP2017000034A (es) Compuestos de imidazopiridazina
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
MY181641A (en) Amino pyran ring derivative and composition and use thereof
PH12017500595A1 (en) Aldosterone synthase inhibitors
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20230918